Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ANRONASDAQ:GNTANASDAQ:JANNASDAQ:TNYA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANROAlto Neuroscience$3.05+4.2%$2.35$1.60▼$17.55$82.68M1.87386,348 shs276,114 shsGNTAGenenta Science$4.29-0.3%$3.98$2.79▼$7.28$78.45M0.6614,669 shs511 shsJANJanOne$2.57$0.22▼$5.26$20.03M2.16229,417 shs139,500 shsTNYATenaya Therapeutics$0.43-1.0%$0.50$0.36▼$4.60$70.01M2.992.48 million shs1.80 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANROAlto Neuroscience+3.70%+19.72%+33.95%-4.71%-75.15%GNTAGenenta Science-1.54%+0.92%+13.02%+8.31%+32.38%JANJanOne0.00%0.00%0.00%0.00%-32.63%TNYATenaya Therapeutics-1.03%-4.27%-4.67%-61.23%-90.26%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANROAlto Neuroscience1.6557 of 5 stars3.31.00.00.03.00.80.6GNTAGenenta Science1.9102 of 5 stars3.53.00.00.00.01.70.0JANJanOneN/AN/AN/AN/AN/AN/AN/AN/ATNYATenaya Therapeutics3.1801 of 5 stars3.53.00.00.00.65.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANROAlto Neuroscience 2.57Moderate Buy$15.40404.26% UpsideGNTAGenenta Science 3.00Buy$25.00482.89% UpsideJANJanOne 0.00N/AN/AN/ATNYATenaya Therapeutics 3.00Buy$6.251,352.14% UpsideCurrent Analyst Ratings BreakdownLatest JAN, GNTA, ANRO, and TNYA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2025ANROAlto NeuroscienceWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$4.00 ➝ $4.005/9/2025TNYATenaya TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.004/25/2025TNYATenaya TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.004/7/2025ANROAlto NeuroscienceHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$10.003/31/2025TNYATenaya TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.003/21/2025ANROAlto NeuroscienceWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform3/13/2025TNYATenaya TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$18.00 ➝ $6.003/12/2025TNYATenaya TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$15.00 ➝ $5.003/12/2025TNYATenaya TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$18.00 ➝ $9.003/11/2025TNYATenaya TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$18.00 ➝ $5.00(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANROAlto NeuroscienceN/AN/AN/AN/AN/AN/AGNTAGenenta ScienceN/AN/AN/AN/A$1.21 per shareN/AJANJanOne$39.61M0.00N/AN/A($0.67) per share0.00TNYATenaya TherapeuticsN/AN/AN/AN/A$2.05 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANROAlto Neuroscience-$36.31M-$2.34N/AN/AN/AN/A-49.28%-33.52%8/12/2025 (Estimated)GNTAGenenta Science-$12.60MN/A0.00N/AN/AN/AN/AN/AN/AJANJanOne-$7.81MN/A0.00N/AN/AN/A-359.71%-70.26%N/ATNYATenaya Therapeutics-$124.08M-$1.16N/AN/AN/AN/A-86.17%-71.14%N/ALatest JAN, GNTA, ANRO, and TNYA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025ANROAlto Neuroscience-$0.59-$0.53+$0.06-$0.56N/AN/A5/7/2025Q1 2025TNYATenaya Therapeutics-$0.18-$0.24-$0.06-$0.24N/AN/A3/20/2025Q4 2024ANROAlto Neuroscience-$0.65-$0.56+$0.09-$0.56N/AN/A3/17/2025Q4 2024TNYATenaya Therapeutics-$0.32-$0.28+$0.04-$0.28N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANROAlto NeuroscienceN/AN/AN/AN/AN/AGNTAGenenta ScienceN/AN/AN/AN/AN/AJANJanOneN/AN/AN/AN/AN/ATNYATenaya TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANROAlto Neuroscience0.0513.1013.09GNTAGenenta ScienceN/A9.31N/AJANJanOneN/A0.150.15TNYATenaya TherapeuticsN/A5.275.27Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANROAlto NeuroscienceN/AGNTAGenenta Science15.13%JANJanOne6.27%TNYATenaya Therapeutics90.54%Insider OwnershipCompanyInsider OwnershipANROAlto Neuroscience11.13%GNTAGenenta Science28.99%JANJanOne3.00%TNYATenaya Therapeutics32.76%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANROAlto NeuroscienceN/A27.07 millionN/AN/AGNTAGenenta Science718.29 million12.99 millionNot OptionableJANJanOne1708.98 million8.71 millionNot OptionableTNYATenaya Therapeutics110162.67 million53.27 millionOptionableJAN, GNTA, ANRO, and TNYA HeadlinesRecent News About These CompaniesBrokerages Set Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Target Price at $6.25May 21 at 2:15 AM | americanbankingnews.comTenaya Therapeutics, Inc.: Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)May 16, 2025 | finanznachrichten.deTenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)May 15, 2025 | globenewswire.comWhy Tenaya Therapeutics, Inc.’s (TNYA) Stock Is Down 5.10%May 15, 2025 | aaii.comTenaya Therapeutics to Present Five Abstracts on Innovative Heart Disease Gene Therapies at ASGCT 2025 Annual MeetingMay 15, 2025 | nasdaq.comTenaya Therapeutics to Highlight Capsid Engineering, Gene Editing and Manufacturing Research at the ASGCT 28th Annual MeetingMay 13, 2025 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Vigil Neuroscience Inc (VIGL), Stevanato Group (STVN) and Tenaya Therapeutics (TNYA)May 11, 2025 | theglobeandmail.comWe're A Little Worried About Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn RateMay 10, 2025 | finance.yahoo.comTenaya Therapeutics Reports Q1 2025 Financial ResultsMay 8, 2025 | tipranks.comTenaya Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 7, 2025 | finance.yahoo.comWhy Tenaya Therapeutics, Inc.’s (TNYA) Stock Is Up 5.03%May 2, 2025 | aaii.comWhy Tenaya Therapeutics, Inc.’s (TNYA) Stock Is Down 6.21%April 30, 2025 | aaii.comH.C. Wainwright maintains Buy on Tenaya Therapeutics stockApril 26, 2025 | investing.comWhy Tenaya Therapeutics, Inc.’s (TNYA) Stock Is Up 6.36%April 26, 2025 | aaii.comTenaya announces interim data from ongoing RIDGE studyApril 25, 2025 | markets.businessinsider.comTenaya Therapeutics Presents Interim Data from RIDGE™ Natural History and Seroprevalence Study of Adults with PKP2-associated ARVC at Heart Rhythm 2025April 24, 2025 | globenewswire.comTenaya Slashes a Third of Workforce to Fund Development of Cardio Gene TherapiesApril 1, 2025 | biospace.comWhy Tenaya Therapeutics, Inc.’s (TNYA) Stock Is Down 11.06%April 1, 2025 | aaii.comTenaya data further builds TN-201 profile, says H.C. WainwrightApril 1, 2025 | markets.businessinsider.comTenaya says TN-201 well tolerated in Phase 1b/2 interim dataApril 1, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeJAN, GNTA, ANRO, and TNYA Company DescriptionsAlto Neuroscience NYSE:ANRO$3.05 +0.12 (+4.23%) Closing price 05/23/2025 03:59 PM EasternExtended Trading$3.00 -0.05 (-1.77%) As of 05/23/2025 04:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder. The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 1 clinical trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 1 clinical trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD. In addition, it develops novel pharmacodynamically synergistic combination and biomarker platform that collects patient-specific data to identify biomarker-characterized patient. The company was incorporated in 2019 and is headquartered in Los Altos, California.Genenta Science NASDAQ:GNTA$4.29 -0.01 (-0.26%) As of 05/23/2025 03:50 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy.JanOne NASDAQ:JANJanOne Inc., a clinical-stage biopharmaceutical company, focuses on identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the unmet medical need for the treatment of pain and addiction. It operates through Biotechnology and Recycling segments. The company's lead product candidate is JAN101, a patented oral and sustained release pharmaceutical composition of sodium nitrite that targets poor blood flow to the extremities in patients with diabetes or peripheral artery disease to treat pain. It also provides turnkey appliance recycling and replacement services for utilities and other sponsors of energy efficiency programs. The company was formerly known as Appliance Recycling Centers of America, Inc. and changed its name to JanOne Inc. in September 2019. JanOne Inc. was founded in 1976 and is headquartered in Las Vegas, Nevada.Tenaya Therapeutics NASDAQ:TNYA$0.43 0.00 (-1.03%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$0.44 +0.00 (+1.07%) As of 05/23/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/19 - 05/23 Trade Desk Silences Critics; Recovery Looks Poised to Continue Booz Allen Hamilton Earnings: 3 Bullish Signals for BAH Stock Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain These ETFs Provide Easy Exposure to Growing International Markets Advance Auto Parts Jumps on Surprise Earnings Beat Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
